Article
Gastroenterology & Hepatology
Baldeep S. Pabla, C. Alex Wiles, James C. Slaughter, Elizabeth A. Scoville, Robin L. Dalal, Dawn B. Beaulieu, David A. Schwartz, Sara N. Horst
Summary: In elderly IBD patients, Vedolizumab showed no significant differences in infection, hospitalization, or surgical intervention-free survival compared to anti-TNF, but had a lower drug discontinuation rate and higher rates of endoscopic remission and response.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Samuel Hsiang Lim, Beatriz Gros, Esha Sharma, Anouk Lehmann, James O. Lindsay, Louise Caulfield, Daniel R. Gaya, Jo Taylor, Jimmy Limdi, Jon Kwok, Elinor Shuttleworth, Anjan Dhar, Gemma Burdge, Christian Selinger, Sara Cococcia, Charles Murray, Karthiha Balendran, Tim Raine, Becky George, Gareth Walker, Robin Aldridge, Peter Irving, Charlie W. Lees, Mark Samaan
Summary: A study conducted in 11 locations in the UK showed that subcutaneous administration of vedolizumab is as effective, safe, and well-tolerated as intravenous administration for patients with inflammatory bowel disease (IBD), and maintains comparable disease control and quality of life as intravenous treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Pharmacology & Pharmacy
Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi
Summary: This study reports the early efficacy and safety outcomes of treating nAMD with intravitreal injections of brolucizumab. The results showed that brolucizumab was highly effective in restoring anatomy and stabilizing visual acuity, but its safety profile requires further evaluation.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Victoria Chatzimavridou-Grigoriadou, Sami Al-Othman, Georg Brabant, Angelos Kyriacou, Jennifer King, Fiona Blackhall, Peter J. Trainer, Claire E. Higham
Summary: In a retrospective evaluation, low-dose tolvaptan was shown to effectively correct hyponatremia due to SIAD in cancer patients, but a significant proportion experienced over-rapid correction, emphasizing the need to avoid the risk of over-rapid correction.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Gastroenterology & Hepatology
Hadrien Alric, Aurelien Amiot, Julien Kirchgesner, Xavier Treton, Mathieu Allez, Yoram Bouhnik, Laurent Beaugerie, Franck Carbonnel, Antoine Meyer
Summary: The VDZ-CDST can predict clinical remission and SFCR at week 48 for vedolizumab, but not for ustekinumab, in CD patients refractory or intolerant to anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2022)
Review
Medicine, General & Internal
Patrycja Dudek, Adam Fabisiak, Hubert Zatorski, Ewa Malecka-Wojciesko, Renata Talar-Wojnarowska
Summary: JAK inhibitors offer a promising treatment strategy for inflammatory bowel disease by potentially affecting multiple cytokine-dependent immune pathways. Despite approved drugs like tofacitinib, thrombotic complications remain a major concern when using JAK inhibitors.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Dermatology
Maddalena Napolitano, Maria Ferrillo, Cataldo Patruno, Massimiliano Scalvenzi, Mirella D'Andrea, Gabriella Fabbrocini
Summary: This study confirms the long-term effectiveness and favorable safety profile of dupilumab in treating moderate-to-severe adult atopic dermatitis, showing significant improvement in disease severity scores and low discontinuation rates due to adverse events.
DERMATOLOGY AND THERAPY
(2021)
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Fernando Rizzello, Carlo Calabrese, Marco Salice, Lucia Calandrini, Hana Privitera, Laura Melotti, Giulia Peruzzi, Nikolas Dussias, Andrea Belluzzi, Eleonora Scaioli, Anastasio Decorato, Antonio Siniscalchi, Eleonora Filippone, Silvio Laureti, Matteo Rottoli, Gilberto Poggioli, Paolo Gionchetti
Summary: The study found a higher incidence of COVID-19 in patients with IBD, but biological therapy does not seem to be a risk factor for infection. Most patients delayed or stopped biological therapy during the pandemic, but a small percentage continued regular treatment.
DIGESTIVE AND LIVER DISEASE
(2021)
Review
Pediatrics
Shengbo Fang, Yanqing Song, Chunyan Zhang, Libo Wang
Summary: Based on low-quality evidence, Vedolizumab shows certain efficacy in children and adolescents with inflammatory bowel disease, with approximately one-third to one-half of patients achieving remission within 22 weeks and a reasonable safety profile. However, more long-term data and high-quality evidence are still needed.
Article
Gastroenterology & Hepatology
Manasi Agrawal, Xian Zhang, Erica J. Brenner, Ryan C. Ungaro, Michael D. Kappelman, Jean-Frederic Colombel
Summary: The study found that COVID-19 outcomes in IBD patients on VDZ were comparable to those on all other therapies. Compared to anti-TNF monotherapy, VDZ monotherapy was more likely to result in hospitalization, but less likely to result in severe COVID-19. Overall, VDZ appears to be safe in IBD patients with COVID-19.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Koji Yokoyama, Yoko Yamamoto, Ryusuke Nambu, Shin-Ichiro Hagiwara, Daiki Abukawa, Tatsuki Mizuochi, Takahiro Kudo, Tomomitsu Sado, Naomi Iwata, Takashi Ishige, Itaru Iwama, Hideki Kumagai, Katsuhiro Arai, Toshiaki Shimizu
Summary: This study evaluated the safety and efficacy of Vedolizumab (VDZ) in pediatric ulcerative colitis (UC) patients in Japan. The results showed that VDZ was a safe and effective treatment option for children with UC. Hematocrit, albumin, and erythrocyte sedimentation rate (ESR) at VDZ initiation may predict VDZ effectiveness. This study is of great importance for treatment decisions in pediatric patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Clinical Neurology
Karin Weissenborn, Sam Gruber, Gerrit M. Grosse, Maria Gabriel, Ramona Schuppner, Hans Worthmann, Omar Abu-Fares, Friedrich Goetz
Summary: The study analyzed the workflow and outcomes of mechanical thrombectomy in acute ischemic stroke patients, identifying causes of treatment delays including medical emergencies, lack of hospital emergency staff prenotification, repeated brain imaging, and transfers from other hospitals. The findings suggest the need for improved operational procedures and patient selection criteria to optimize endovascular treatment.
FRONTIERS IN NEUROLOGY
(2021)
Article
Pediatrics
Kanokkarn Sunkonkit, Mohammed Alzaid, Lena Xiao, Colin Massicotte, Suhail Al-Saleh, Reshma Amin
Summary: This study retrospectively analyzed the indications, results, and outcomes of inpatient polysomnography (PSG) in pediatric patients at SickKids, Toronto, Canada, from July 2018 to July 2021. The study showed that inpatient PSG is an important diagnostic tool that guides medical and surgical interventions. Future multicenter studies are needed to compare indications for inpatient PSGs across institutions and develop evidence-based clinical practice guidelines.
PEDIATRIC PULMONOLOGY
(2023)
Article
Gastroenterology & Hepatology
David A. Schwartz, Laurent Peyrin-Biroulet, Karen Lasch, Shashi Adsul, Silvio Danese
Summary: This study demonstrated that vedolizumab could significantly improve symptoms and quality of life in patients with fistulizing Crohn's disease, with positive effects on scar tissue formation in particular. Additionally, the addition of an extra dose at week 10 did not affect treatment outcomes. No new safety concerns were identified.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
